Pharmacologic management of isolated low high-density lipoprotein syndrome

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Preventive Cardiology

Background:

• High-density lipoprotein (HDL) cholesterol plays a crucial role in cardiovascular health, exhibiting protective properties against atherosclerosis.
• Epidemiologic studies consistently demonstrate an inverse relationship between HDL cholesterol levels and cardiovascular risk.
• Low HDL cholesterol is a prevalent issue, particularly with rising rates of obesity, diabetes, and metabolic syndrome, increasing the risk for myocardial infarction, stroke, and other cardiovascular events.

Purpose of the Study:

• To review the clinical significance of low high-density lipoprotein (HDL) cholesterol and discuss current and emerging therapeutic strategies.
• To highlight the importance of lifestyle modifications as a first-line approach to managing low HDL cholesterol.
• To evaluate the efficacy and safety of various pharmacological interventions for low HDL cholesterol.

Main Methods:

• Review of epidemiologic studies, clinical trial data, and pharmacological mechanisms related to HDL cholesterol.
• Analysis of the association between HDL levels and cardiovascular disease risk, including data from the Framingham study.
• Examination of therapeutic options, including lifestyle changes, approved medications (niacin, fibrates, statins), and investigational drugs.

Main Results:

• Low HDL cholesterol is a significant independent risk factor for cardiovascular disease, with a 1-mg/dL increase in HDL associated with a 2-3% decrease in risk.
• Lifestyle measures are the primary strategy for managing low HDL, while pharmacologic options like niacin and fibrates show varying efficacy.
• Statins demonstrate risk reduction across all HDL levels, whereas early trials of cholesteryl ester transfer protein inhibitors (e.g., Torcetrapib) were halted due to increased mortality and adverse cardiovascular events.

Conclusions:

• Isolated low HDL cholesterol is clinically important and warrants therapeutic consideration, despite underutilization by clinicians.
• Lifestyle interventions and judicious use of existing medications are key to managing low HDL cholesterol.
• Emerging therapies, including beta-glucans, Apo-A1 mimetic peptides, and ACAT inhibitors, offer future promise for effectively raising HDL levels and mitigating cardiovascular risk.